Drug Trial Radar · NCT06453265
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 28, 2024
Primary completion
Nov 6, 2024
Study completion Nov 6, 2024
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH)
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.
Conditions
- Abuse, Drug
Interventions
Cebranopadol- 600 ugDrug
Dose ascending cohorts \- Cebranopadol 600 ug single dose
Cebranopadol- 800ugDrug
Dose ascending cohorts \- Cebraopadol 800 ug single dose
Cebranopadol- 1000ugDrug
Dose ascending cohorts \- Cebranopadol 1000 ug single dose
Treatment A:Drug
Cebranopadol, dose determined in Part A
Treatment BDrug
Oxycodone HCl IR 40 mg
Treatment CDrug
Placebo
QualificationDrug
Oxycodone 40mg
QualificationDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Drug Liking VAS EmaxTime frame: 48 hrs of Tmax for each treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ohio Clinical Trials, Inc.
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.